| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.28% | 61.84% | 60.76% | 59.40% | 61.51% | 59.53% | 55.67% | 50.88% | 49.42% | 44.46% | 34.78% | 30.84% |
| Operating Margin | 12.58% | 7.76% | -6.70% | -25.85% | -40.14% | -33.50% | -67.62% | -105.12% | -77.25% | -8.38% | -34.16% | -43.17% |
| EBITDA Margin | 13.05% | 8.42% | -5.66% | -24.65% | -38.82% | -32.04% | -65.97% | -103.19% | -74.84% | -7.14% | -32.71% | -40.75% |
| Net Margin | 13.43% | 8.58% | -5.91% | -22.96% | -40.22% | -33.62% | -69.45% | -105.57% | -53.67% | -10.92% | -35.19% | -43.50% |
| Current Ratio | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 | 1.96 | 2.23 | 2.53 | 7.07 | 1.77 | 1.99 | 2.04 |
| Quick Ratio | 4.86 | 3.06 | 1.70 | 1.78 | 2.00 | 1.25 | 1.46 | 1.96 | 6.35 | 0.88 | 1.24 | 1.26 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | 0.00 | 0.57 | — |
| ROE | 22.71% | 18.55% | -17.35% | -57.69% | -85.50% | -121.32% | -157.24% | -122.58% | -21.13% | -29.36% | -134.76% | -78.01% |
| ROA | 16.34% | 12.52% | -8.98% | -30.60% | -46.90% | -51.94% | -79.87% | -78.89% | -18.14% | -14.82% | -46.42% | -49.18% |
| Asset Turnover | 1.22 | 1.46 | 1.52 | 1.33 | 1.17 | 1.54 | 1.15 | 0.75 | 0.34 | 1.36 | 1.32 | 1.13 |
| Book Value / Share | 0.90 | 0.59 | 0.38 | 0.41 | 0.47 | 0.27 | 358.33 | 494.09 | 1.21 | 0.27 | 0.04 | 0.06 |
Niagen Bioscience Inc. is a bioscience company headquartered in Los Angeles, California. The company specializes in advancing NAD+ science to support cellular health and healthy aging through its proprietary Niagen platform, a patented NAD+-boosting ingredient known as nicotinamide riboside (NR). Niagen powers leading brands such as Tru Niagen, an oral supplement for consumer use, and Niagen Plus, which includes pharmaceutical-grade intravenous and injectable formulations available at clinics across the U.S. Niagen Bioscience Inc. operates ISO-accredited laboratories and maintains a reference standards business providing natural products, phytochemicals, and botanical reference materials for quality assurance in food, supplements, and research. It also runs the ChromaDex External Research Program, supplying high-quality NAD+ precursors to academic and government researchers worldwide. The company discovers, develops, and commercializes proprietary ingredient technologies targeting dietary supplements, food, beverages, skin care, and pharmaceutical markets, emphasizing science-backed innovation, clinical research, and regulatory compliance.